Blood
Articles in this Issue
Ph-like B-cell acute lymphoblastic leukemia in a Mexican pediatric cohort: Molecular features and prognostic implications
Abstract Introduction: Genomic and transcriptomic studies have highlighted the biological heterogeneity of B-ALL, allowing identification of...
Etranacogene dezaparvovec in haemophilia b: Report of 1ST patient receiving HEMGENIX® in Spain
Abstract INTRODUCTION Etranacogene dezaparvovec (ED, Hemgenix®) is a gene therapy approved by European Medicines Agency (EMA) in 2023 for ad...
The role of hepatocyte nuclear factors in the externalization of phosphatidylserine in sickle erythrocytes
Abstract In sickle cell disease (SCD), the asymmetric distribution of phospholipids on red blood cells (RBCs) leads to the exposure of phosp...
The national burden of opoid use disorder on hospital outcomes in sickle cell disease: A database review and analysis
Abstract Introduction: Sickle cell disease (SCD) affects approximately 100,000 individuals in the U.S. and frequently leads to hospitalizati...
An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis
Abstract Background: The t(11;14) translocation occurs in 50-60% patients with systemic AL amyloidosis. Venetoclax, an oral BCL2 inhibitor,...
Paradoxical venous thromboembolism in immune thrombocytopenia : A national study of mortality,anticoagulation gaps and racial disparities
Abstract Background: Immune thrombocytopenia (ITP) is an acquired autoimmune disorder charcahterized by isolated thrombo...
Treatment response, relapse and survival of hospitalized adult primary warm autoimmune hemolytic anemia: A multicenter retrospective cohort study
Abstract Introduction: Primary warm autoimmune hemolytic anemia (pwAIHA) is a rare autoimmune disease leading to acceler...
TBI based VS chemotherapy based myeloablative conditioning in T cell replete haploidentical transplant
Abstract Introduction: Limited data compare total body irradiation (TBI)-based versus chemotherapy-based myeloablative conditioning (MAC) in...
A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia
Abstract Background: Venetoclax (VEN), a selective B-cell lymphoma-2 (BCL-2) inhibitor, significantly improves outcomes in acute myeloid leuk...
Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era
Abstract Background: Hematopoietic Cell Transplantation – Comorbidity Index (HCT-CI) is possibly the most commonly used prognostic score to...
Favorable safety and therapeutic efficacy of a novel humanized anti-ADAMTS13 antibody in acquired von willebrand syndrome: A preclinical study
Abstract Introduction Acquired von Willebrand syndrome (AVWS) results from the excessive proteolytic cleavage of von Willebrand factor (VWF)...
Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement
Abstract Introduction: Proliferative chronic myelomonocytic leukemia (CMML) is an increasingly recognized blood cancer involving pro-inflamma...
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL
Abstract Introduction: In the primary analysis of TRANSCEND FL (NCT04245839), an open-label, pivotal study, liso-cel showed high response ra...
Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials
Abstract Introduction: Anemia is associated with poor quality of life and shorter survival in patients with myelofibrosis (MF), as recognize...
VWF:ADAMTS13 ratio is associated with white matter hyperintensity
Abstract Background: ADAMTS13 exerts an antithrombotic effect by cleaving highly prothrombotic high molecular weight Von Willebrand Factor (...
Reactivating mutant p53 in T cells enhances anti-tumor activity in Acute Myeloid Leukemia
Abstract Emerging evidence from our group suggests that mutant TP53 may play a critical role in T-cell exhaustion and the impairment of anti...
Low utilization of cancer genetics referrals in newly diagnosed Acute Myeloid Leukemia
Abstract Background: Current clinical guidelines recommend evaluation for suspected hereditary myeloid malignancy predisposition syndromes (...
Cytokine signatures predict response, progression, and immune-related toxicity in Sézary syndrome patients treated with mogamulizumab
Abstract Introduction Sézary syndrome is a rare, aggressive cutaneous T-cell lymphoma characterized by erythroderma, lym...
Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling
Abstract Immunotherapy has transformed the treatment landscape of multiple myeloma (MM), harnessing T-cell–mediated cytotoxicity with the pr...
Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single‑center retrospective cohort
Abstract Therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid leukemias (t-AML) are dramatic late complications of therapies...
CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial
Abstract Background: Despite improved treatments, overall survival of patients with acute myeloid leukemia (AML) remains poor, especially fo...
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion
Abstract Background: AML associated with TP53 mutations (TP53mut) often exhibits a complex karyotype, demonstrates a poor response to intensi...
Real-world outcomes for anti-CD38 monoclonal antibody-naive and exposed patients receiving treatment for multiple myeloma
Abstract Introduction: For patients (pts) with multiple myeloma (MM) experiencing relapsed or refractory (RRMM) disease, several novel thera...
First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry
Abstract Background: Venetoclax, a selective BCL-2 inhibitor, has transformed the treatment of chronic lymphocytic leukemia (CLL). Randomize...
Comparative risk of major adverse cardiovascular events in polycythemia vera patients treated with ruxolitinib, hydroxyurea, or interferon: A real-world, propensity-matched cohort study
Abstract Background: Vascular complications are the primary cause of morbidity and mortality in patients with polycythemia vera (PV), yet con...